Artificial intelligence and machine learning help researchers to shape large datasets, but incredible computing power is still needed to muscle through biological data in a reasonable time. That's where machines such as Anton 2 and BioHive-1 come into play.

Investors often hear of the significant difficulties in ramping up industrial manufacturing processes, such as for automobiles or wind turbines. But the most challenging scale up might occur in biopharma and industrial biotech.